Charles Schwab
NPCE icon

Charles Schwab’s Neuropace NPCE Stock Holding History

Charles Schwab’s Portfolio NPCE Stock Details NPCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.24M Buy
77,831
+8,020
+11% +$129K ﹤0.01% 2942
2026
Q1 		$918K Sell
69,811
-6,342
-8% -$95.1K ﹤0.01% 2924
2025
Q4 		$1.18M Buy
76,153
+7,304
+11% +$97.7K ﹤0.01% 2872
2025
Q3 		$710K Hold
68,849
– – ﹤0.01% 3059
2025
Q2 		$767K Buy
68,849
+29,612
+75% +$370K ﹤0.01% 2986
2025
Q1 		$482K Buy
39,237
+2,700
+7% +$33.8K ﹤0.01% 3094
2024
Q4 		$409K Hold
36,537
– – ﹤0.01% 3201
2024
Q3 		$255K Hold
36,537
– – ﹤0.01% 3310
2024
Q2 		$276K Buy
+36,537
New +$369K ﹤0.01% 3387
2022
Q2 		– Sell
-16,968
Closed -$140K – 3611
2022
Q1 		$140K Sell
16,968
-480
-3% -$4.14K ﹤0.01% 3363
2021
Q4 		$176K Hold
17,448
– – ﹤0.01% 3376
2021
Q3 		$277K Hold
17,448
– – ﹤0.01% 3281
2021
Q2 		$416K Buy
+17,448
New +$405K ﹤0.01% 3200

Other funds holding NPCE

PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Charles Schwab's NPCE Position: Q2 2026 in Review

Charles Schwab increased its Neuropace (NPCE) stake by 11% in Q2 2026, buying an estimated $129K and bringing the position to 77,831 shares worth $1.24M. The position accounts for ﹤0.01% of the portfolio, ranked #2942.

Charles Schwab first reported a position in NPCE in Q2 2021 and has held it in 13 quarters since. 113 funds tracked by Wall St. Rank hold NPCE as of Q2 2026.

  • Charles Schwab held 77,831 shares of Neuropace worth $1.24M as of Q2 2026.
  • Charles Schwab bought 8,020 Neuropace shares in Q2 2026, an estimated $129K.
  • Neuropace made up ﹤0.01% of Charles Schwab's portfolio in Q2 2026, its #2942 holding.
  • Charles Schwab first reported a position in Neuropace in Q2 2021 and has held it in 13 quarters since.
  • 113 funds tracked by Wall St. Rank held Neuropace as of Q2 2026.

Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.